Skip to main content

Table 2 VTEs according to treatment arm, histologic subtype and treatment phase

From: High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08

 Overall
N = 300
Investigational Arm
N = 149
Control Arm
N = 151
Adeno-carcinoma
N = 189
Squamous Cell Carcinoma
N = 111
Overall (N)8.7% (26b)9.4% (14a)7.9% (12)11.1% (21a)4.5% (5)
Preoperative (N = 300)6.7% (20b)8.0% (12a)5.3% (8)9% (17a)2.7% (3)
Ind-CT1.3% (4)1.3% (2)1.3% (2)1.6% (3)0.9% (1)
RCT5.6% (16b)7.1% (10a)4.1% (6)7.7% (14a)1.9% (2)
Postoperative (N = 259)3.1% (8)3.1% (4)3.1% (4)3.5% (6)2.3% (2)
  1. aOne of these patients had two simultaneous grade 3 VTEs in the RCT phase
  2. bTwo of these patients had two separate grade 3 VTEs at different time points